I am not a professional advisor. Seek professional advice before investing or trading.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Or a merger/buyout would do it.
Relief & NeuroRX Leadership (Brief Summary)
Here are a few highlights about a few of the leaders at Relief & NeuroRX. Each of these individuals bring with them impressive educational backgrounds, extensive world-class experience, and connections into the highest levels of government and some of the largest companies in the United States. These individuals, along with other equally-impressive team members, are leading RLF-100 through the FDA process and preparing for launch.
Dr. Jonathan Javitt – NeuroRX Founder, CEO, and Chairman of the Board
• Dr Javitt is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School.
• He was appointed to healthcare leadership roles under Presidents Reagan, Bush Sr, Clinton, and Bush Jr.
• Dr. Javitt led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer.
• He held leadership roles in seven successful healthcare IT and biopharma startups with public exits.
• He previously served as expert consultant to the World Bank, the National Institutes of Health, the Health Care Financing Administration, Department of Veterans Affairs, and the ministries of health of United Kingdom, Sweden, Australia, Japan, and the Netherlands.
Dr. Ram (Raghuram Selvaraju) – Relief Chairman of the Board
• Holds a BS in Molecular Biology, a MS in Biological Sciences, a MS in Molecular Biology, a Ph.D. in Cellular Immunology and Molecular Neuroscience and an MBA from Cornell University, Carnegie Mellon University, and University of Geneva.
• Dr. Ram has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV, and is widely quoted in national publications such as Barron’s and The Wall Street Journal, The Pink Sheet, BioWorld Today, and BioCentury.
• He was formally the Vice President in Equity Research, Managing Director, and Senior Analyst for multiple companies throughout his career.
Robert Besthof – NeuroRX Chief of Operations
• Mr. Besthof is a global biopharmaceutical executive who has spent his career at Eli Lilly & Pfizer.
• At Pfizer, he was head of the entire neuro science and pain division and was responsible for $10b of drugs.
Wayne Pines – NeuroRX Regulatory & Patient Advocacy Adviser
• Previously served as FDA Associate Commissioner.
• Was recently in the news as a long-term friend and advisor to Dr. Hahn (FDA Commissioner).
Peter Egon de Svastich – Relief Board Member
• Mr. de Svastich is a Managing General Partner of GEM.
• He holds a Business degree from Princeton, LLB/JD from Yale Law School, and LATF from Fletcher School of Law.
• He has been Principal Executive Officer, President, Principal Financial Officer, Treasurer and Secretary at Global Group Enterprises Corp.
• He has been the Chief Financial Officer, Chief Operating Officer, and Chief Compliance Officer for a number of hedge funds and funds of funds.
• Mr. de Svastich also served as a Partner, Chief Financial Officer, and Chief Compliance Officer of Alpha Equity Management.
Thomaz Burckhardt - Relief Board Member
• After completing his law studies, he held various positions in the areas of asset management and capital markets at leading international banks UBS, Deutsche Bank, JP Morgan, and Credit Suisse.
• He specializes in asset management, capital market transactions and mergers & acquisitions.
Thanks for taking the time to put this together.
Apology accepted... we need to know what's out there moving the stock (so thanks for that), but we also need to know the reliability of the source (as you've honestly pointed out). It didn't make much difference this time, but just everyone keep in mind that those last few minutes of volume and price increase could be a combination of pumpers and their associated bag holders who may sell at the first rumor of trouble. Hopefully the rumor is true, but if not, then we can't let this fake pump ruin credibility for our ACE.
Where did you hear that?
Well... that scares me stiff.
Well... i think in the US most are using Viagra or similar for ED... on-demand pills.
Curious... its self injection? Where is that done? Hopefully the shoulder or thigh :D
I’m on the road. Is Fauci saying anything?
No... it has been silent for quite some time; however, here are my thoughts and I'm sure many others on this board:
- No news, no pumping, likely indicates this is not a pump-n-dump and the professional, highly-connected leadership team is working through the FDA, political and big pharma landscapes.
- Hiring of a CMO and expanding trials into Europe indicates confidence in progress being made in the US and thus they are spending money to expand
- Preparing and publishing financials, website, pre-prints, partnerships, etc indicate a go-forward posture.
If these guys have a good product that will be approved by the FDA, they will become inundated with orders worldwide... its a massive effort behind the scenes that takes a while to come together. They already know what the results are, and if it were me running the show, I would not be pushing the FDA to hurry and approve, because we would not yet be in position to fulfill the need. Give these pros some time to pull the whole solution together; otherwise it could become a disaster with worldwide demand.
Right. Here are all the dates on the official clinical trial site:
Official Title: Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19
Estimated Study Start Date : July 1, 2020
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : November 30, 2020
https://clinicaltrials.gov/ct2/show/NCT04360096
LOL... I think that's the second time I've overlooked that. I'll fix my source notes. Thanks.
I think we get the intravenous study results any day now over the next couple weeks. That's also a separate clinical trial due sooner. Trial: NCT04311697
I think the reopening of schools may be re-seeding a new wave of covid cases that will not become apparent until November/December. Here's why...
The plan for most schools is to allow kids to return, follow CDC guidelines, and track which kids have classes with each other, so they know who has been exposed when a covid case shows up. Once someone has covid, they will quarantine (send home) everyone who has been exposed.
Here's the problem...
1) Kids aren't doing a good job following CDC guidelines. They hang out together, where masks below their noses, touch surfaces, wipe eyes, mouths, etc.
2) Exposures can't really be tracked... Once someone is identified with covid, the school has a list of students who have supposedly been exposed and need to quarantine. But there are 2 problems with this approach: First... by the time the school learns about the child with covid, they could have been spreading it around for up to 2 weeks already. There is no way the school really knows who was exposed because; Second... the school isn't accurately tracking all exposures during lunch periods, football practices, recess, extra curricular activities, restroom usage, after-school socializing, cross-exposure through family members/siblings, cross-exposure in the community. So... during the 2 weeks the kids were running around exposing everyone, those people were running around exposing others, who were running around exposing more...
...and so a new wave of covid cases may have already been seeded enough to cause a wave that would only become apparent in a couple months or so. Only time will tell.
Correct... the trial ending in March 2022 is an 80 patient study with a PREVENTATIVE inhaler. Trial: NCT04536350
The US trial of 288 patients estimated to complete Nov 31, 2020 is the TREATMENT inhaler. Trial: NCT04360096
The US trial of 288 patients is the horse we're all betting on. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
Correct... and we are just starting to see the impact of schools reopening. In a couple more weeks, it will be apparent that we need a treatment as a backdrop before we can go full swing back into regular life again. Here is what's happening this week in the Orlando area alone:
• More than 800 students and staff in Central Florida public schools faced quarantine in the last week because of exposure to the coronavirus.
• Nearly 400 of the quarantine cases were from Osceola County after positive tests were reported at about a dozen schools.
• Other Osceola schools with double-digit quarantine numbers included Harmony High School with 57, Gateway High School with 45 and Kissimmee Middle School with 44.
• The Orange school district reported 20 new COVID-19 cases at 13 schools late Tuesday and said 188 people had been told to quarantine.
• The bulk of the quarantines were from Olympia High School, which school leaders ordered closed on Sunday after learning 136 students, 19 teachers and one bus driver had been exposed to the coronarvirus.
• 32 quarantines stemmed from cases reported at Edgewater High School and Lake Whitney Elementary School.
• In Seminole County, officials said 128 people were in quarantine, with new positive cases reported at three schools.
• In Lake County, the school district reported 103 students and seven staff members quarantined last week.
https://www.orlandosentinel.com/news/education/os-ne-covid-cases-schools-update-20200909-7g5fkzwze5doxhw3wxex4roq6a-story.html
Well said.
Indeed it is.
Very nice!
Very good point. Thanks.
Ok thanks, so it’s not necessarily the RS itself that is negative, but rather the deceptive dilution that often accompanies a RS in the OTC/penny arena. That makes sense thanks. And I agree that RLFTF and Gem are not looking to pull-off a deceptive dilution scheme, since they seem to be running the show in a very professional manner. Thanks to everyone’s replies... appreciate it.
Hey guys... help me out here, as I don’t have any experience with reverse splits with OTC penny stocks. For example, if I own 400 shares of RLFTF at 50c each, then that means I own $200 worth of stock. If RLFTF does a 4:1 reverse split, then I will end up with 100 shares at $2 each, still worth $200...right? What am I missing? Why is a reverse split such a negative thing? Thanks in advance.
Yes. It’s low volume cuz it’s a small amount of new investors and a low amount of day traders flipping the stock over and over in a single day. I’m good with that while we continue to wait for news.
When we get a price spike and then it comes back down again, that’s a good measure of day traders coming in & out for a quick buck. What I’m looking at is the steady daily increases that represent new investors coming onboard as they discover this drug and company.
Great video all the way to the end. Very cool to see his perspective prior to being involved in a worldwide Covid solution.
You're welcome gang.
Please use this version, as it more clearly presents the information for the Aug 28 update.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158136340
Updated Summary of known facts about RLFTF: Aviptadil RLF-100 VIP
(updated 9/6/20)
Several individuals have requested that I provide an update to my original summary about RLFTF. This post highlights several key updates since then.
Original Post on August 23, 2020
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157819838
New Note: Aviptadil is a safe, synthetic version of a naturally occurring peptide in the human body, which increases surfactant production in the lungs.
Update August 28, 2020
On August 28, an official pre-print that “describes the first 6 patients with Acute Respiratory Failure” was released, providing new details about their incredible results:
• Before aviptadil, each of the patients were "showing active signs of clinical deterioration... despite receiving maximal intensive care for COVID-19 related respiratory failure”.
• The document states that after taking aviptadil, all 6 patients survived, all showed x-ray improvements within the first 72 hours, and all showed improvement in blood oxygenation.
• “The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent.”
https://www.preprints.org/manuscript/202008.0640/v1
Update August 31, 2020
Relief up-listed from the OTC Pink exchange to the OTCQB exchange, which is “recognized by the Securities and Exchange Commission as an established public market” that is “designed for early-stage and developing companies”. “This will allow a broader range of investors to invest in Relief Stock.”
https://relieftherapeutics.com/relief-announces-successful-up-listing-from-otc-pink-to-otcqb-and-capital-increase-from-its-share-subscription-facility-with-gem/
Update September 2, 2020
On September 2nd, a fourth FDA clinical trial #NCT04536350 was initiated for an inhaled version of aviptadil as a preventative treatment. The trial will take place in Switzerland, and is expected to finish in December of 2021.
The trial document that was submitted made a case for aviptadil’s safety, as well as its long-term role for ARDS and other medical conditions:
The Covid front-runner remdesivir “is the first and so far, only approved treatment for COVID-19”, but unfortunately, it “did not find significant improvement in COVID- 19 patients”. Also, other antiviral drugs “have not found a significant benefit”, and thus “there is still a desperate need for an effective, safe treatment for COVID-19”.
Aviptadil has been approved safe in Europe for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction, and ARDS. ARDS in particular “is a known lethal complication” that “may result in organ failure”. In the early 2000’s, seven out of “eight patients with severe ARDS on mechanical ventilation” were “successfully extubated”.
Aviptadil was also given to animals with lung injury, and showed to “restore barrier function” and to “protect the lung and other organs from failure”.
Additionally, “healthy volunteers have shown that inhaled aviptadil is well tolerated with few adverse effects.”
Update September 4, 2020
On September 4th, Relief announced they have hired Dr. Corte as the new CMO (Chief Medical Officer) to head up the clinical development of aviptadil in Europe, which confirms Relief’s commitment to additional international expansion.
Relief’s Chairman said that Dr. Corte “will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon."
In this article, we also received further confirmation that “aviptadil has broad potential to help patients with other acute and chronic lung diseases, as well as earlier-stage COVID-19 patients”.
https://relieftherapeutics.com/relief-appoints-gilles-della-corte-m-d-as-chief-medical-officer/
Interesting. I wonder what the results would be if they ran a placebo controlled, double blind, randomized clinical trial for using prayers on Covid patients.
I agree the impact to the pandemic will be dramatic.
First... it will make respirators predominantly unnecessary.
Then... as it works it’s way down to moderate cases, it will alleviate hospitals and staff and people will get processed and treated and sent home much faster.
Then.... once the home-version of the inhaler is produced, very few will need to go to the hospital.
Once that level is reached, there will be far fewer people to spread the virus in communities. It will remain an issue in certain parts of the world for a while, and then will always be among us thereafter, but at a dramatically lower threat.
You’re welcome :)
Summary of known facts about RLFTF: Aviptadil RLF-100 VIP
(updated 9/5/20)
Several individuals have requested that I provide an update to my original summary about RLFTF. Given my limited time, I am only able to provide a few key updates to my original post.
Original Post on August 23, 2020
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157819838
New Note: Aviptadil is a safe, synthetic version of a naturally occurring peptide in the human body, which increases surfactant production in the lungs.
Update August 28, 2020
An official pre-print that “describes the first 6 patients with Acute Respiratory Failure” was released, providing new details about their incredible results:
• Each of the patients were "showing active signs of clinical deterioration... despite receiving maximal intensive care for COVID-19 related respiratory failure”.
• The document states that all 6 patients survived, all showed x-ray improvements within the first 72 hours, and all showed improvement in blood oxygenation.
• “The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent.”
https://www.preprints.org/manuscript/202008.0640/v1
Update August 31, 2020
Relief up-listed from the OTC Pink exchange to the OTCQB exchange, which is “recognized by the Securities and Exchange Commission as an established public market” that is “designed for early-stage and developing companies”. “This will allow a broader range of investors to invest in Relief Stock.”
Update September 2, 2020
On September 2nd, a fourth FDA clinical trial #NCT04536350 was initiated for an inhaled version of aviptadil as a preventative treatment. The trial will take place in Switzerland, and is expected to finish in December of 2021.
The trial document that was submitted made a case for aviptadil’s safety, as well as its long-term role for ARDS and other medical conditions:
The Covid front-runner remdesivir “is the first and so far, only approved treatment for COVID-19”, but unfortunately, it “did not find significant improvement in COVID- 19 patients”. Also, other antiviral drugs “have not found a significant benefit”, and thus “there is still a desperate need for an effective, safe treatment for COVID-19”.
Aviptadil has been approved safe in Europe for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction, and ARDS. ARDS in particular “is a known lethal complication” that “may result in organ failure”. In the early 2000’s, seven out of “eight patients with severe ARDS on mechanical ventilation” were “successfully extubated”.
Aviptadil was also given to animals with lung injury, and showed to “restore barrier function” and to “protect the lung and other organs from failure”.
Additionally, “healthy volunteers have shown that inhaled aviptadil is well tolerated with few adverse effects.”
Update September 4, 2020
On September 4th, Relief announced they have hired Dr. Corte as the new CMO (Chief Medical Officer) to head up the clinical development of aviptadil in Europe, which confirms Relief’s commitment to additional international expansion.
Relief’s Chairman said that Dr. Corte “will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon."
In this article, we also received further confirmation that “aviptadil has broad potential to help patients with other acute and chronic lung diseases, as well as earlier-stage COVID-19 patients”.
Hey Squash... thanks for the compliment and the credit. I wasn't planning on updating, but you're not the first to ask, so let me see if I get some spare time this weekend.
Hi JTorence... In and of itself, it is somewhat minor news; however, reading further into it, here are a few things I see:
First, this guy isn't cheap... he has a background in clinical trail planning and in laying foundations for product launches. He also has decades of expertise in a number of areas that make him a great fit for Relief.
He will "be responsible for the clinical development of aviptadil in Europe." In other words, they are simultaneously launching efforts in Europe... which is no small task regarding time, money, energy, resources, etc.
As per the chairman: "He will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon."
In the press release, the CMO stated: "aviptadil has broad potential to help patients with other acute and chronic lung diseases", further confirming our expectations of other applications.
This new CMO is basically Europe's version of Dr. Javitt. The clinical trials management company (Virtuoso Sarl) will "set up and run aviptadil clinical trials in Europe", similar to what NeuroRX does here in the US.
So the PR says quite a bit:
1) European efforts (and related expenses) demonstrate Relief's confidence in their product and the progress they are making.
2) It confirms Relief is still expecting US approval soon.
3) It confirms Relief has a vision beyond Covid.
4) It indicates Relief is forming a template for rolling out the drug worldwide... hire a pro to oversee the rollout region, contract with a clinical trials management team, partner with a manufacturer, partner with a distributor.
All great stuff! Certainly no regular OTC-penny-stock-pump.
Trump: “…the therapeutics over the short term and also knowing you have the therapeutics from the standpoint of the mind… from the standpoint of the mind… it’s great.”
Relief - An easing sensation from the standpoint of the mind.
JK LOL
That would be funny :) But I've never know him to speak in code or have much creativity in his press conference lol.
No just that trump mentioned earlier today that he will have a 5pm news conference... he said it as he was discussing therapeutics, so no promises, but we're hoping he says more.
But I will be looking for clues... "we have some very powerful therapeutics that will provide a lot of relief to many many Americans I can tell you that"